Infant Bacterial Therapeutics AB logo

IBT B - Infant Bacterial Therapeutics AB News Story

SEK114 15.0  15.2%

Last Trade - 07/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £110.3m
Enterprise Value £73.8m
Revenue £n/a
Position in Universe 878th / 1838

Infant Bacterial Therapeutics receives additional patent protection in China

Thu 15th April, 2021 6:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210415:nGNEbzMpm8&default-theme=true


Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent
office has issued a decision to grant approval of IBTs patent application
entitled: A method of activating lactic acid bacteria, which protects
formulations of Lactobacillus reuteri including IBP-9414. IBT is currently
developing its drug candidate IBP-9414 in Phase III for the prevention of NEC
and improvement of feeding tolerance in preterm infants.  

The invention covers a novel way to activate the freeze-dried bacteria and
corresponding patent applications for the invention are currently pending in
additional important future markets including the US and Europe. IBT recently
received similar patent protection in Japan. This patent increases the
existing protection of IBTs drug candidate IBP-9414 in addition to Orphan Drug
Exclusivity and biological data protection already established in the USA and
EU. 

The Chinese patent expires in 2036 and the IBP-9414 product covered by this
patent is intended to be marketed in China after future marketing
authorization.

“We are very pleased that IBT has succeeded in expanding our intellectual
property protection for IBP-9414 through the approved patent in an important
additional market” says Staffan Strömberg, Chief Executive Officer of IBT.

About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a
product in Phase III with a vision to develop drugs influencing the infant
microbiome, and thereby prevent or treat rare diseases affecting infants.

IBT is currently developing the drug candidate IBP-9414, for the prevention of
necrotizing enterocolitis (“NEC”) and improvement of feeding tolerance in
premature infants. IBP-9414 contains the active substance Lactobacillus
reuteri, which is a human bacterial strain naturally present in breast milk.
The product portfolio also includes another project, IBP-1016, for the
treatment of gastroschisis, a severe and rare disease affecting infants. By
developing these drugs, IBT has the potential to fulfill unmet needs for
diseases where there are currently no prevention or treatment therapies
available.

Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in
Stockholm. The company’s class B-shares shares are listed on Nasdaq
Stockholm, Mid-cap (IBT B).

For additional information please contact: 
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 70 670 1226
info@ibtherapeutics.com
www.ibtherapeutics.com

Publication

This information is information that Infant Bacterial Therapeutics AB is
obliged to make public pursuant to the EU Market Abuse Regulation and the
Securities Markets Act.  The information was submitted for publication,
through the agency of the contact persons set out above, at 19:00 CET on April
15, 2021. 

 

Attachment
*     PR 20210414 China ENG
(https://ml-eu.globenewswire.com/Resource/Download/378cc728-57ed-4f3e-9653-247f1d85747c)
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.